Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
CA 2295375 A1 · Owner: Novopharm Biotech Inc. · Inventors: Dan, Michael D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to monoclonal antibody 4B5 and antigen binding fragments that specifically bind to the antibodies specific for GD2. Also disclosed are polynucleotide and polypeptide derivatives based on 4B5 including single chain V region molecules and fusion proteins and various , pharmaceutical compositions. When administered to an individual the 4B5 , antibody is effective in diagnosing and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease particularly , melanoma, neuroblastoma glioma, soft tissue sarcoma, and lung carcinomas. Patients who are in remission as a result of traditional modes of cancer therapy can be treated …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 8, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 8, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 8, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.